LON:DPHDechra Pharmaceuticals Share Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Dechra Pharmaceuticals plc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add GBX 2,890 -12.00 (-0.41 %) (As of 07/3/2020 04:00 PM ET) Add Compare Share Today's Range 2,890Now: GBX 2,890▼ 2,95050-Day Range 2,622MA: GBX 2,801.88▼ 2,92652-Week Range 388Now: GBX 2,890▼ 3,090Volume150,447 shsAverage Volume282,452 shsMarket Capitalization£3.12 billionP/E Ratio103.96Dividend Yield1.12%BetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsDividendInsider TradesHeadlines Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians worldwide. It operates through European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development segments. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and locomotion and pain management products for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies. It also provides pet nutrition products for dogs and cats under the Specific brand; distributes veterinary pharmaceuticals and equipment; and offers financial services. The company markets its products through wholesaler and distributor networks. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom.Read More Beat the Market (BTM) Rank™ 1.1 Analyst's Opinion Consensus RatingDechra Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of GBX 2,931.25, Dechra Pharmaceuticals has a potential upside of 1.4% from its current price of GBX 2,890.Amount of Analyst CoverageDechra Pharmaceuticals has only been the subject of 3 research reports in the past 90 days. Previous Next 2.3 Community Rank Outperform VotesDechra Pharmaceuticals has received 335 “outperform” votes. (Add your “outperform” vote.)Underperform VotesDechra Pharmaceuticals has received 386 “underperform” votes. (Add your “underperform” vote.)Community SentimentDechra Pharmaceuticals has received 53.54% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Dechra Pharmaceuticals and other stocks. Vote “Outperform” if you believe DPH will outperform the S&P 500 over the long term. Vote “Underperform” if you believe DPH will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldDechra Pharmaceuticals has a dividend yield of 1.12%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthDechra Pharmaceuticals does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Dechra Pharmaceuticals is 115.11%. Payout ratios above 75% are not desirable because they may not be sustainable. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Dechra Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought £19,828.40 in company stock and sold GBX 0 in company stock. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Dechra Pharmaceuticals are expected to decrease by -100.00% in the coming year, from GBX 9,876 to GBX 0 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dechra Pharmaceuticals is 103.96, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 16.17.Price to Earnings Ratio vs. SectorThe P/E ratio of Dechra Pharmaceuticals is 103.96, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 24.82.Price to Book Value per Share RatioDechra Pharmaceuticals has a P/B Ratio of 6.23. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 1.1Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.29 out of 5 stars Industry, Sector and Symbol Stock Exchange LON Industry Drug Manufacturers - Major Sub-IndustryN/A SectorMedical Current SymbolLON:DPH Previous Symbol CUSIPN/A CIKN/A Webwww.dechra.com Phone+44-1606-814730Debt Debt-to-Equity Ratio64.00 Current Ratio0.94 Quick Ratio0.55Price-To-Earnings Trailing P/E Ratio103.96 Forward P/E Ratio0.29 P/E GrowthN/A Sales & Book Value Annual Sales£498.90 million Price / Sales6.26 Cash FlowGBX 62.44 per share Price / Cash Flow46.28 Book ValueGBX 464.10 per share Price / Book6.23Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees1,437 Outstanding Shares108,011,000Market Cap£3.12 billion Next Earnings Date9/7/2020 (Estimated) OptionableNot Optionable LSE:DPH Rates by TradingView Receive DPH News and Ratings via Email Sign-up to receive the latest news and ratings for DPH and its competitors with MarketBeat's FREE daily newsletter. Dechra Pharmaceuticals (LON:DPH) Frequently Asked Questions How has Dechra Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Dechra Pharmaceuticals' stock was trading at GBX 2,472 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, DPH stock has increased by 16.9% and is now trading at GBX 2,890. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Dechra Pharmaceuticals? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dechra Pharmaceuticals in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Dechra Pharmaceuticals. When is Dechra Pharmaceuticals' next earnings date? Dechra Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, September 7th 2020. View our earnings forecast for Dechra Pharmaceuticals. How often does Dechra Pharmaceuticals pay dividends? What is the dividend yield for Dechra Pharmaceuticals? Dechra Pharmaceuticals declared a dividend on Monday, February 24th. Stockholders of record on Thursday, March 5th will be paid a dividend of GBX 10.29 per share on Wednesday, April 8th. This represents a dividend yield of 0.37%. The ex-dividend date of this dividend is Thursday, March 5th. The official announcement can be seen at this link. View Dechra Pharmaceuticals' dividend history. What price target have analysts set for DPH? 4 brokerages have issued twelve-month price objectives for Dechra Pharmaceuticals' stock. Their forecasts range from GBX 2,510 to GBX 3,200. On average, they expect Dechra Pharmaceuticals' share price to reach GBX 2,931.25 in the next twelve months. This suggests a possible upside of 1.4% from the stock's current price. View analysts' price targets for Dechra Pharmaceuticals. Has Dechra Pharmaceuticals been receiving favorable news coverage? Media stories about DPH stock have been trending negative this week, InfoTrie reports. The research group ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Dechra Pharmaceuticals earned a media sentiment score of -2.2 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the company's share price in the next few days. View the latest news about Dechra Pharmaceuticals. Who are some of Dechra Pharmaceuticals' key competitors? Some companies that are related to Dechra Pharmaceuticals include Hutchison China MediTech (HCM), Opthea (OPT), Mayne Pharma Group (MYX), Vectura Group (VEC), Medical Developments International (MVP), Eco Animal Health Group (EAH), BEXIMCO PHARMAC/S GDR REGS (BXP), Allergy Therapeutics (AGY), Trilogy International Partners (TRL), Recce Pharmaceuticals (RCE), NanoViricides (NNVC), Futura Medical (FUM), Vita Life Sciences (VLS), Pharmaxis (PXS) and Antisense Therapeutics (ANP). View all competitors. What other stocks do shareholders of Dechra Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Dechra Pharmaceuticals investors own include 32Red (TTR), Supergroup (SGP), JD Sports Fashion (JD), Ashtead Group (AHT), Cranswick (CWK), Drax Group (DRX), RPC Group (RPC), Robert Walters (RWA), SkyePharma (SKP) and Barratt Developments (BDEV). Who are Dechra Pharmaceuticals' key executives? Dechra Pharmaceuticals' management team includes the following people: Mr. Ian D. Page, CEO, MD & Exec. Director (Age 58)Mr. Richard John Cotton, CFO & Director (Age 58)Dr. Anthony Gerard Griffin, MD of Dechra Veterinary Products for Europe & Exec. Director (Age 56)Ms. Katy Clough, Group HR DirectorMr. Mike Eldred, Pres of North America (Age 49) What is Dechra Pharmaceuticals' stock symbol? Dechra Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "DPH." How do I buy shares of Dechra Pharmaceuticals? Shares of DPH and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Dechra Pharmaceuticals' stock price today? One share of DPH stock can currently be purchased for approximately GBX 2,890. How big of a company is Dechra Pharmaceuticals? Dechra Pharmaceuticals has a market capitalization of £3.12 billion and generates £498.90 million in revenue each year. Dechra Pharmaceuticals employs 1,437 workers across the globe. What is Dechra Pharmaceuticals' official website? The official website for Dechra Pharmaceuticals is www.dechra.com. How can I contact Dechra Pharmaceuticals? Dechra Pharmaceuticals' mailing address is 24 Cheshire Business Park Cheshire Avenue, NORTHWICH, CW9 7UA, United Kingdom. The company can be reached via phone at +44-1606-814730. This page was last updated on 7/5/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
